Search
Hereditary Angioedema (HAE) Paid Clinical Trials in Ohio
A listing of 6 Hereditary Angioedema (HAE) clinical trials in Ohio actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Hereditary Angioedema (HAE)
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Ohio currently has 6 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. These trials are conducted in various cities, including Cincinnati, Columbus, Cleveland and Dayton.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Recruiting
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/30/2025
Locations: Bernstein Clinical Research Center, LLC, Cincinnati, Ohio +1 locations
Conditions: Hereditary Angioedema
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Recruiting
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/29/2025
Locations: Bernstein Clinical Research Center, LLC, Cincinnati, Ohio
Conditions: Hereditary Angioedema
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Recruiting
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
04/09/2025
Locations: KalVista Investigative Site, Toledo, Ohio
Conditions: Hereditary Angioedema
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Recruiting
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Optimed Research, Columbus, Ohio
Conditions: Hereditary Angioedema
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/06/2025
Locations: KalVista Investigative Site, Cincinnati, Ohio +1 locations
Conditions: Hereditary Angioedema
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/08/2024
Locations: Ionis Investigative Site, Cincinnati, Ohio +1 locations
Conditions: Hereditary Angioedema
1 - 6 of 6